Abdelfattah N, Kumar P, Wang C, Leu JS et al (2022) Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun 13(1):767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adusumilli L, Facchinello N, Teh C, Busolin G, Le MT, Yang H, Beffagna G, Campanaro S, Tam WL, Argenton F et al (2020) Mir-7 controls the dopaminergic/oligodendroglial fate through Wnt/β-catenin signaling regulation. Cells 9:711. https://doi.org/10.3390/cells9030711

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS (2005) SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 65:3542–3547

Article  CAS  PubMed  Google Scholar 

Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16(1):6–21

Article  CAS  PubMed  Google Scholar 

Brown Nicholas F et al (2022) “Survival outcomes and prognostic factors in glioblastoma: retrospective review of a multicenter population-based cohort”. Cancers (Basel), 14 13 article 3161. https://pmc.ncbi.nlm.nih.gov/articles/PMC9265012/

Cascio CL, McNamara JB, Melendez EL, Lewis EM, Dufault ME, Sanai N, Lo Cascio C, Plaisier CL, Mehta S (2021) Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells. JCI Insight. https://doi.org/10.1172/jci.insight.149232

Article  PubMed  PubMed Central  Google Scholar 

Chen J-A et al (2011) Mir-17-3p controls spinal neural progenitor patterning by regulating Olig2/Irx3 cross-repressive loop. Neuron 69(4):721–735

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P (2016) Microrna therapeutics: discovering novel targets and developing specific therapy. Perspect Clin Res 7(2):68–74. https://doi.org/10.4103/2229-3485.179431

Article  PubMed  PubMed Central  Google Scholar 

Desai K et al (2025) Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat Commun 16:1. https://doi.org/10.1038/s41467-024-54861-3

Article  CAS  Google Scholar 

Egawa N, Shindo A, Hikawa R, Kinoshita H, Liang AC, Itoh K et al (2019) Differential roles of epigenetic regulators in the survival and differentiation of oligodendrocyte precursor cells. Glia 67:718–728. https://doi.org/10.1002/glia.23567

Article  PubMed  Google Scholar 

Fan C, Kim D, An H, Park Y (2023) Identifying an oligodendrocyte enhancer that regulates Olig2 expression. Hum Mol Genet 32(5):835–846. https://doi.org/10.1093/hmg/ddac249

Article  CAS  PubMed  Google Scholar 

Fu Y, Yi Y, Shao Y, Jiang J, Deng Q (2025) Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations. Front Immunol 16:1561388. https://doi.org/10.3389/fimmu.2025.1561388

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, Clarke J, Solomon D, Scheffler A, Witte J, Lambing H, Okada H, Berger M, Chehab F, Butowski NA (2023) Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect. Neuro-Oncol Adv 5(1):vdad115. https://doi.org/10.1093/noajnl/vdad115

Article  Google Scholar 

Gregath A, Lu QR (2018) Epigenetic modifications: insight into oligodendrocyte lineage progression, regeneration, and disease. FEBS Lett 592(7):1063–1078. https://doi.org/10.1002/1873-3468.12999

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamed AA, Hua K, Trinh QM, Simons BD, Marioni JC, Stein LD, Dirks PB (2025) Gliomagenesis mimics an injury response orchestrated by neural crest-like cells. Nature 638:499–509. https://doi.org/10.1038/s41586-024-08356-2

Krgoswami (2024) Beyond DNA: how molecular modifications drive inheritance. Medium. https://medium.com/resilient-mindset/beyond-dna-how-molecular-modifications-drive-inheritance-b5f905bbae17

Li C, Tang Z, Zhang W et al (2021) GEPIA 2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res 49:W242–W246. https://doi.org/10.1093/NAR/GKAB418

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Lim C, Dismuke T et al (2025) Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat Commun 16:1091. https://doi.org/10.1038/s41467-024-54861-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ligon Keith L et al (2017) “Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas”. Cell Cycle 16 18 1654–1660. PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5602295/

Liu X, Wang A, Shi Y, Dai M, Liu M, Cai HB (2023) Protacs in epigenetic cancer therapy: current status and future opportunities. Molecules 28(3):1217. https://doi.org/10.3390/molecules28031217

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsumoto S, Banine F, Feistel K et al (2016) Brg1 directly regulates Olig2 transcription and is required for oligodendrocyte progenitor cell specification. Dev Biol 413(2):173–187. https://doi.org/10.1016/j.ydbio.2016.04.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matter, Maria Luisa, and Anne N. Mungall (2009) “Contributions of extracellular matrix signaling and tissue architecture to nuclear mechanisms and spatial organization of gene expression control.” PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC2728154/

Medical Xpress (2025) Potential new therapy for childhood brain cancer could heal treatment-resistant tumors. https://medicalxpress.com/news/2025-02-potential-therapy-childhood-brain-cancer.html

Morgan E, Mason W (2017) What are the prospects for combination therapy for glioblastoma? Expert Rev Neurother 17(10):947–949. https://doi.org/10.1080/14737175.2017.1351300

Article  CAS  PubMed  Google Scholar 

Moyon S, Ma D, Huynh JL, Coutts DJC, Zhao C, Casaccia P, Franklin RJM (2017) Efficient remyelination requires DNA methylation. Eneuro. https://doi.org/10.1523/ENEURO.0336-16.2017

Article  PubMed  PubMed Central  Google Scholar 

Myers BL, Brayer KJ, Paez-Beltran LE et al (2024) Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration. Nat Commun 15:10363. https://doi.org/10.1038/s41467-024-54750-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noorani I, de la Rosa J (2023) Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat Commun 14:5909. https://doi.org/10.1038/s41467-023-41694-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onciul R, Brehar FM, Dumitru AV, Crivoi C, Covache-Busuioc RA, Serban M, Radoi PM, Toader C (2025) Predicting overall survival in glioblastoma patients using machine learning: an analysis of treatment efficacy and patient prognosis. Front Oncol 15:1539845. https://doi.org/10.3389/fonc.2025.1539845

Article  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American Brain Tumor Association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncol 18(suppl_1):i1–i50. https://doi.org/10.1093/neuonc/nov297

Article  PubMed  Google Scholar 

Pawlowski KD, Duffy JT, Babak MV, Balyasnikova IV (2023) Modeling glioblastoma complexity with organoids for personalized treatments. Trends Mol Med 29(4):282–296. https://doi.org/10.1016/j.molmed.2023.01.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pine AR, Cirigliano SM, Nicholson JG, Hu Y, Linkous A, Miyaguchi K, Edwards L, Singhania R, Schwartz TH, Ramakrishna R, Pisapia DJ, Snuderl M, Elemento O, Fine HA (2020) Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. Cancer Discov 10(7):964–979. https://doi.org/10.1158/2159-8290.CD-20-0057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Azazmeh N, Rashid R, Lin R, Cusick M, N Reynolds AR, R Fassinou AC, Ayoub G, Malinowski S, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS, . . . Beroukhim R (2025) A window-of-opportunity trial reveals m